165 related articles for article (PubMed ID: 38196507)
1. Synergistic Effects of Nanoscale CaO
Wang Y; Ju S; Zhou H; Bai Y; Zhou C; Liu J; Dong X; Zheng C
Int J Nanomedicine; 2024; 19():137-154. PubMed ID: 38196507
[TBL] [Abstract][Full Text] [Related]
2. Nanoscale CaO
Wang Y; He X; Zhou C; Bai Y; Li T; Liu J; Ju S; Wang C; Xiang G; Xiong B
Acta Biomater; 2022 Dec; 154():536-548. PubMed ID: 36241014
[TBL] [Abstract][Full Text] [Related]
3. Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101.
Bao X; Shen N; Lou Y; Yu H; Wang Y; Liu L; Tang Z; Chen X
Theranostics; 2021; 11(12):5955-5969. PubMed ID: 33897892
[TBL] [Abstract][Full Text] [Related]
4. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice.
Sasaki K; Nishina S; Yamauchi A; Fukuda K; Hara Y; Yamamura M; Egashira K; Hino K
Cell Mol Gastroenterol Hepatol; 2021; 11(3):739-762. PubMed ID: 33191170
[TBL] [Abstract][Full Text] [Related]
6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
8. TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer.
Wang Z; Zhu M; Dong R; Cao D; Li Y; Chen Z; Cai J; Zuo X
J Nanobiotechnology; 2023 Nov; 21(1):440. PubMed ID: 37993847
[TBL] [Abstract][Full Text] [Related]
9. Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses.
Zhang XS; Zhou HC; Wei P; Chen L; Ma WH; Ding L; Liang SC; Chen BD
World J Gastrointest Oncol; 2023 Dec; 15(12):2138-2149. PubMed ID: 38173440
[TBL] [Abstract][Full Text] [Related]
10. Yangyin Fuzheng Jiedu Prescription exerts anti-tumor immunity in hepatocellular carcinoma by alleviating exhausted T cells.
Yan F; Wang X; Xie Y; Liu X; Yu L; Wang P; Li T; Wang S; Li W; Yang Z
Phytomedicine; 2021 Oct; 91():153722. PubMed ID: 34488188
[TBL] [Abstract][Full Text] [Related]
11. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma.
Xie Y; Yan F; Wang X; Yu L; Yan H; Pu Q; Li W; Yang Z
Cancer Med; 2023 Feb; 12(3):3237-3259. PubMed ID: 36043445
[TBL] [Abstract][Full Text] [Related]
13. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
15. A combination of check-point blockade and α-galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo.
Ishii K; Shimizu M; Kogo H; Negishi Y; Tamura H; Morita R; Takahashi H
Immunobiology; 2020 Jan; 225(1):151860. PubMed ID: 31812347
[TBL] [Abstract][Full Text] [Related]
16. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
Wang H; He X; Fang D; Wang X; Guan J; Shi ZW; Chen X
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101853. PubMed ID: 34923183
[TBL] [Abstract][Full Text] [Related]
18. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
19. The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma.
Zhu Y; Chen M; Xu D; Li TE; Zhang Z; Li JH; Wang XY; Yang X; Lu L; Jia HL; Dong QZ; Qin LX
Cell Mol Immunol; 2022 Jun; 19(6):726-737. PubMed ID: 35459855
[TBL] [Abstract][Full Text] [Related]
20. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
